Georgetown University

This study tested a low dose of nilotinib, a drug used for leukemia, in 37 people with mild to moderate Alzheimer's disease. The goal was to see if the drug is safe and can reach the brain to affect proteins linked to Alzheimer's, like tau and amyloid. Participants took the drug …

This study tests whether bosutinib, a drug currently used for leukemia, can safely treat dementia with Lewy bodies (DLB). The trial involves 30 adults aged 25–90 with DLB, who will take either bosutinib or a placebo daily for three months. Researchers will monitor side effects an…

This study tested the safety and effects of nilotinib, a cancer drug, in 43 people with Dementia with Lewy Bodies (DLB). DLB is a common type of dementia that shares features with Parkinson's and Alzheimer's. The goal was to see if nilotinib is safe and changes brain biomarkers, …

This Phase 2 study tested whether low doses of nilotinib, a drug already approved for leukemia, are safe and affect brain markers in 75 people with Parkinson's disease. Participants took either a placebo or one of two low doses of nilotinib daily for 12 months. The goal was to se…

This study tested a combination of two oral drugs, ribociclib and everolimus, in 12 people with metastatic pancreatic cancer that had stopped responding to standard chemotherapy. The goal was to find the right dose and see if it could slow tumor growth. The trial was small and ea…

This study tested a new combination of drugs (ABT-888 plus chemotherapy) in 64 people with pancreatic cancer that had spread. The goal was to see if adding ABT-888, which blocks cancer cells from fixing DNA damage, could make chemotherapy work better and shrink tumors. The study …

This study looked at whether a 3-session peer coaching program over the phone could help young women (ages 21–30) who have a family history of BRCA mutations. The goal was to see if it reduces cancer-related distress and helps them make informed decisions about genetic counseling…

This completed study tested a software platform called OR PathTrac that monitors bacteria in operating rooms. The goal was to see if giving hospitals feedback on where germs spread could help reduce surgical site infections. Over 800 adults having surgery took part. The study foc…